Abstract
Epidemiological data suggest that Non Steroidal Anti Inflammatory Drugs (NSAIDs) and Cyclooxygenase 2 (COX2) inhibitors (COXibs) can exert chemopreventive and antitumour effects in many human neoplasia. This is particularly true in colon cancer (CC), where the regular assumption of these molecules has been shown to exert chemopreventive and chemotherapeutic effects. Since the late ‘90s, there has been a progressive increase in experimental evidence, indicating that in CC the antiproliferative effects of NSAIDs and COXibs could be both dependent on and independent of COXs inhibition, and that these effects do not necessarily exclude each other. This review will examine some of these COX-independent cellular pathways, with a focus on those involved in the inhibition of CC cells proliferation through transcription factors crosstalk.
Keywords: Colon carcinoma, inflammation, non steroidal anti inflammatory drugs, proliferation, transcription factor, tumour.
Current Cancer Drug Targets
Title:Non Steroidal Anti Inflammatory Drugs As Gatekeepers Of Colon Carcinoma Highlight New Scenarios Beyond Cyclooxygenases Inhibition
Volume: 16 Issue: 2
Author(s): Tiziana Guarnieri
Affiliation:
Keywords: Colon carcinoma, inflammation, non steroidal anti inflammatory drugs, proliferation, transcription factor, tumour.
Abstract: Epidemiological data suggest that Non Steroidal Anti Inflammatory Drugs (NSAIDs) and Cyclooxygenase 2 (COX2) inhibitors (COXibs) can exert chemopreventive and antitumour effects in many human neoplasia. This is particularly true in colon cancer (CC), where the regular assumption of these molecules has been shown to exert chemopreventive and chemotherapeutic effects. Since the late ‘90s, there has been a progressive increase in experimental evidence, indicating that in CC the antiproliferative effects of NSAIDs and COXibs could be both dependent on and independent of COXs inhibition, and that these effects do not necessarily exclude each other. This review will examine some of these COX-independent cellular pathways, with a focus on those involved in the inhibition of CC cells proliferation through transcription factors crosstalk.
Export Options
About this article
Cite this article as:
Guarnieri Tiziana, Non Steroidal Anti Inflammatory Drugs As Gatekeepers Of Colon Carcinoma Highlight New Scenarios Beyond Cyclooxygenases Inhibition, Current Cancer Drug Targets 2016; 16 (2) . https://dx.doi.org/10.2174/1568009615666150827093012
DOI https://dx.doi.org/10.2174/1568009615666150827093012 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular Imaging of Apoptosis In Vivo with Scintigraphic and Optical Biomarkers – A Status Report
Anti-Cancer Agents in Medicinal Chemistry Monitoring of Treatment-Induced Apoptosis in Oncology with PET and SPECT
Current Pharmaceutical Design Molecular Signatures of Biomarkers in Cancer Development, Diagn osis, and its Prognostic Accuracy
Current Biomarkers (Discontinued) Control of Inflammatory Bowel Disease and Colorectal Cancer by Synthetic Vitamin D Receptor Ligands
Current Medicinal Chemistry Applications of Mesoporous Materials as Excipients for Innovative Drug Delivery and Formulation
Current Pharmaceutical Design Subject Index To Volume 2
Current Nutrition & Food Science Inhibitors of the Immunoproteasome: Current Status and Future Directions
Current Pharmaceutical Design Vitamin, Mineral, and Drug Absorption Following Bariatric Surgery
Current Drug Metabolism TGF-β1 Signalling, Connecting Aberrant Inflammation and Colorectal Tumorigenesis
Current Pharmaceutical Design In Silico Studies in Drug Research Against Neurodegenerative Diseases
Current Neuropharmacology Poly(ADP-Ribosylation): Beneficial Effects of Its Inhibition
Current Enzyme Inhibition Drug Metabolism and Pharmacokinetic Diversity of Ranunculaceae Medicinal Compounds
Current Drug Metabolism An Update on JAK Inhibitors
Current Medicinal Chemistry Disease-Related Changes in TRPV1 Expression and Its Implications for Drug Development
Current Topics in Medicinal Chemistry Nanostructural Hybrid Sensitizers for Photodynamic Therapy
Current Pharmaceutical Design Progress in Imaging Agents of Cell Apoptosis
Anti-Cancer Agents in Medicinal Chemistry Chronopharmaceutics: A Promising Drug Delivery Finding of the Last Two Decades
Recent Patents on Drug Delivery & Formulation Cyclin D1 Gene Silencing by siRNA in Ex Vivo Human Tissue Cultures
Current Drug Delivery Unusual Food Allergy: AlioideaAllergic Reactions Overview
Recent Patents on Inflammation & Allergy Drug Discovery 30 Years Lost in Anesthesia Theory
Cardiovascular & Hematological Agents in Medicinal Chemistry